The Pre-Trade Check That Takes 5 Minutes

Analyst Targets

• Cantor Fitzgerald: Upgraded to Overweight from Neutral; target raised to $460 from $300 (Oct 7, 2026)
• JPMorgan: Neutral; target raised to $393 from $316
• Street consensus: Buy; average 12-month target approximately $424

What Happened Thursday Night

Humana shares surged as much as 13% in after-hours trading Thursday after CMS released 2027 Medicare Advantage star ratings, while Alignment Healthcare tumbled after its largest contract fell below the four-star cutoff. By Friday morning, HUM had traded as high as $450.50 on October 8, with shares settling near $445.

Contract H5216, which covers about 2.4 million members, increased to 4 stars from 3.5, making Humana again eligible for bonus payments on that contract. That single half-star move is the event. Everything else follows from it.

Company Profile

Humana is one of the largest managed care providers in the U.S. and a major player in the Medicare Advantage space. The company brought in $40.9 billion in revenue last quarter, up 26% on membership growth and more generous MA rates. Beyond insurance, it operates CenterWell, its provider services arm, which management is positioning as a margin recovery engine independent of the stars cycle.

Why the Four-Star Line Is a Financial Event

CMS assigns Medicare Advantage plans ratings from 1 to 5 stars based on clinical outcomes, customer experience, and plan performance. Contracts at 4 stars or above qualify for quality bonus payments that increase federal funding per member. The newly published ratings will primarily affect payments in 2028.

The dollar magnitude matters here. A reduction from 4 stars to 3.5 stars can cost an insurer a material amount of bonus and rebate economics. Recovering H5216 to 4 stars does not restore Humana to its prior peak bonus level overnight, but it reopens the door.

The 2027 ratings do not change this year’s results. They feed payments in 2028, which is why a single half-star move on a large contract can be worth hundreds of millions of dollars.

The Collapse, and the Recovery

Humana suffered a major ratings collapse heading into the 2025 rating year, when the proportion of members enrolled in plans rated at least 4 stars plunged from 94% to 25%, dealing a significant blow to its earnings outlook. That figure slipped again to about 20% for 2026. Thursday’s CMS release confirmed a step up for 2027: H5216’s return to 4 stars is the pivotal move Humana’s management had been signaling.

Broader Market Context

CMS reported that approximately 37% of MA-PD contracts earned 4 stars or higher for 2027, and weighted by enrollment, approximately 71% of MA-PD enrollees are in contracts with 4 or more stars. Fifteen MA-PD contracts earned 5 stars for 2027. The competitive picture is uneven: Aetna, a CVS Health company, has said that more than 69% of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, positioning it as one of the higher-performing large publicly traded MA organizations.

Alignment’s situation is the mirror image of Humana’s. Its largest California contract was downgraded to 3.5 stars from 4, and that contract represented about 81% of the company’s membership as of September 2025. Alignment has disputed the rating, arguing it does not accurately reflect the contract’s performance on evidence-based quality measures.

Bull / Base / Bear Scenarios

Bull: H5216 holds at 4 stars through the 2028 bonus calculation, Humana’s remaining lower-rated contracts also improve, and the company rebuilds bonus revenue to a level closer to its prior base. A restored 4-star position allows Humana to continue its margin recovery and provides financial flexibility to rebuild profitability. Stock tests the $500 range.

Base: H5216 at 4 stars locks in meaningful 2028 bonus improvement. Management executes the plan exit strategy covering roughly 600,000 members, concentrating enrollment in higher-rated contracts. Earnings recover gradually toward the mid-cycle target. Stock digests the overnight gain and consolidates near current levels.

Bear: CMS methodology shifts again at next year’s rating cycle, or elevated medical cost trends persist and compress margins regardless of bonus recovery. Star rating recovery, CMS reimbursement rates, and CenterWell ramp-up remain critical execution risks for the long-term thesis. A renewed drop below 4 stars on H5216 would erase Thursday’s gains and then some.

Technical Overlay

HUM gapped Thursday from a closing price near $388 to an intraday high of $450.50, a move that now sits above the prior 52-week high of $428.88. Gaps of this size on catalyst events frequently see partial fills within two to four weeks as momentum traders trim. The $388-400 zone, former resistance, becomes the first support level to watch on any pullback. The 52-week low of $163.11 reflects how far the stock has already traveled in its recovery; the nearer-term base is the $350-370 range that held through August and September.

Bottom Line

The 13% overnight move is not irrational. Clearing the four-star line on a roughly 2.4-million-member contract restores access to potentially hundreds of millions in annual bonus and rebate economics that Humana had lost across recent rating cycles. The stock has more than doubled from its 52-week low, and the consensus target near $424 was set before Thursday’s news. What investors must now weigh is how much of the 2028 bonus recovery is priced at current levels versus what incremental improvement in the remaining contracts could still add. The next formal test is Q3 earnings on November 6.